The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28089699 |
63 |
Investigation of piperazine benzamides as humanß |
Merck |
| 28523097 |
37 |
Similarity- and Substructure-Based Development ofß |
Philipps University Marburg |
| 3560162 |
3 |
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. |
TBA |
| 2878080 |
1 |
6,7-Dichloro-1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline . A structurally novel beta-adrenergic receptor blocking agent. |
TBA |
| 6124637 |
18 |
Syntheses and adrenergic agonist properties of ring-fluorinated isoproterenols. |
TBA |
| 11459642 |
39 |
Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 1. |
Nippon Roche Research Center |
| 27876250 |
60 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH |
Jagiellonian University Medical College |
| 26988801 |
55 |
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents. |
Jagiellonian University Medical College |
| 26709102 |
142 |
Discovery of Vibegron: A Potent and Selectiveß3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder. |
Merck Research Laboratories |
| 26125514 |
40 |
Discovery of Novel Indazole Derivatives as Highly Potent and Selective Humanß3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects. |
Asahi Kasei Pharma |
| 25065493 |
92 |
The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-actingß2-adrenoceptor agonist. |
Novartis Institutes For Biomedical Research |
| 24835980 |
98 |
Discovery of TD-4306, a long-actingß2-agonist for the treatment of asthma and COPD. |
Theravance |
| 24813741 |
110 |
Multivalent design of long-actingß(2)-adrenoceptor agonists incorporating biarylamines. |
Theravance |
| 16640337 |
47 |
Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists. |
Glaxosmithkline |
| 23614528 |
121 |
Synthesis and in vitro and in vivo characterization of highlyß1-selectiveß-adrenoceptor partial agonists. |
University of Nottingham |
| 23614494 |
2 |
Structure-based fragment screening is demonstrated to be a practical lead discovery method for a representative G-protein-coupled receptor. |
Pfizer |
| 23517028 |
2 |
Biophysical fragment screening of theß1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. |
Heptares Therapeutics |
| 21870877 |
119 |
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for humanß-adrenoceptors. |
University of Nottingham |
| 17507221 |
58 |
Identification and SAR of potent and selective non-peptide obeline somatostatin sst1 receptor antagonists. |
Novartis Institutes For Biomedical Research |
| 11806709 |
63 |
Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres. |
Glaxosmithkline |
| 22932315 |
28 |
An investigation into the structure-activity relationships associated with the systematic modification of theß(2)-adrenoceptor agonist indacaterol. |
Novartis Institutes For Biomedical Research |
| 22079756 |
219 |
From libraries to candidate: the discovery of new ultra long-acting dibasicß2-adrenoceptor agonists. |
Astrazeneca |
| 22178551 |
46 |
A multivalent approach to the discovery of long-actingß(2)-adrenoceptor agonists for the treatment of asthma and COPD. |
Theravance |
| 21925889 |
48 |
The discovery of long-acting saligeninß2 adrenergic receptor agonists incorporating a urea group. |
Glaxosmithkline |
| 21696967 |
51 |
The discovery of long-acting saligeninß2 adrenergic receptor agonists incorporating hydantoin or uracil rings. |
Glaxosmithkline |
| 21723724 |
91 |
Design-driven LO: the discovery of new ultra long acting dibasicß2-adrenoceptor agonists. |
Astrazeneca |
| 20462258 |
50 |
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. |
Glaxosmithkline |
| 19317397 |
62 |
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups. |
Glaxosmithkline |
| 9548813 |
53 |
The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. |
Smithkline Beecham Pharmaceuticals |
| 11454468 |
35 |
Discovery and SAR of org 24598-a selective glycine uptake inhibitor. |
Organon Research and Development Group |
| 21486038 |
177 |
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. |
H. Lundbeck |
| 22386241 |
46 |
Synthesis and pharmacological evaluation of carbamic acid 1-phenyl-3-(4-phenyl-piperazine-1-yl)-propyl ester derivatives as new analgesic agents. |
Sk Biopharmaceuticals |
| 22313227 |
78 |
Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype. |
National Institute of Mental Health |
| 24900353 |
6 |
Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity. |
TBA |
| 24900360 |
24 |
Synthesis and Cardiac Imaging of (18)F-Ligands Selective for ß1-Adrenoreceptors. |
TBA |
| 21726069 |
98 |
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. |
University of Namur |
| 21207959 |
69 |
Syntheses of 2-amino and 2-halothiazole derivatives as high-affinity metabotropic glutamate receptor subtype 5 ligands and potential radioligands for in vivo imaging. |
National Institute of Mental Health |
| 20875743 |
90 |
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity rela |
Pfizer |
| 20931963 |
112 |
Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome. |
Aska Pharmaceutical |
| 20684563 |
176 |
Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. |
H. Lundbeck |
| 20181479 |
177 |
Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles. |
Merck Research Laboratories |
| 19963380 |
38 |
Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. |
Hunter College and The Graduate Center of The City University of New York |
| 19608416 |
29 |
Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6. |
Astellas Pharma |
| 19581100 |
162 |
Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists. |
Astellas Pharma |
| 19232786 |
72 |
Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists. |
Astellas Pharma |
| 18651730 |
123 |
Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety. |
Astellas Pharma |
| 16562853 |
22 |
Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro. |
Tom'S of Maine |
| 18307290 |
97 |
Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I. |
Astellas Pharma |
| 16451077 |
86 |
Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists. |
Pfizer |
| 16198561 |
99 |
Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis. |
Novartis Institutes For Biomedical Research |
| 15603933 |
28 |
Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist. |
Fujisawa Pharmaceutical |
| 15482914 |
25 |
Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750. |
Pfizer |
| 12213075 |
70 |
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). |
Purdue University |
| 11311069 |
64 |
(4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists. |
Wyeth-Ayerst Research |
| 11585444 |
295 |
From hit to lead. Analyzing structure-profile relationships. |
Universities of Lille |
| 7658429 |
31 |
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431). |
Abbott Laboratories |
| 2319556 |
16 |
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities. |
Berlex Laboratories |
| 1976812 |
62 |
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity. |
Berlex Laboratories |
| 6126588 |
12 |
Use of (S)-(trifloxymethyl)oxirane in the synthesis of a chiral beta-adrenoceptor antagonist, (R)- and (S)-9-[[3-(tert-butylamino)-2-hydroxypropyl]oximino]fluorene. |
TBA |
| 15203136 |
39 |
(+/-)8-Amino-5,6,7,8-tetrahydroisoquinolines as novel antinociceptive agents. |
Virginia Commonwealth University |
| 21863888 |
9 |
Efficient conversion of a nonselective norepinephrin reuptake inhibitor into a dual muscarinic antagonist-ß2-agonist for the treatment of chronic obstructive pulmonary disease. |
Pfizer |
| 21783363 |
10 |
Synthesis and in vitro evaluation of derivatives of theß¿?-adrenergic receptor antagonist HX-CH 44. |
University of Toronto |
| 20036561 |
39 |
Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists. |
Medical University of Lublin |
| 21353541 |
25 |
Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective humanß3 adrenergic receptor agonists. |
Merck Research Laboratories |
| 20833036 |
221 |
Thienopyrimidines asß3-adrenoceptor agonists: hit-to-lead optimization. |
4Sc |
| 20813948 |
63 |
Spiroindolones, a potent compound class for the treatment of malaria. |
Swiss Tropical and Public Health Institute |
| 20655218 |
72 |
A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators. |
Novartis Institutes For Biomedical Research |
| 20684592 |
83 |
Identification of potent and selective amidobipyridyl inhibitors of protein kinase D. |
Novartis Institutes For Biomedical Research |
| 20684591 |
87 |
Identification of orally available naphthyridine protein kinase D inhibitors. |
Novartis Institutes For Biomedical Research |
| 20620058 |
41 |
Smoothened antagonists for hair inhibition. |
Pfizer |
| 20591666 |
66 |
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase. |
Università |
| 20434333 |
111 |
A vHTS approach for the identification of beta-adrenoceptor ligands. |
4Sc |
| 20384344 |
42 |
Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice. |
Meiji Seika Kaisha |
| 20096576 |
41 |
Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. |
Boehringer Ingelheim Pharma |
| 19646882 |
72 |
Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways. |
University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and The Informatics Institute of Umdnj |
| 19643607 |
26 |
Studies towards topical selective beta2-adrenoceptor agonists with a long duration of action. |
Boehringer Ingelheim Pharma |
| 19875286 |
44 |
Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as beta2-adrenoceptor agonists. |
Boehringer Ingelheim Pharma |
| 19783143 |
65 |
Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead. |
Novartis Institutes For Biomedical Research |
| | 21 |
Serotonin 5-HT4 agonist activity of a series of meso-azanoradamantane benzamides |
TBA |
| | 38 |
Carboxyl-promoted enhancement of selectivity for the β3 adrenergic receptor. Negative charge of the sulfonic acid BMS-187413 introduces-β3 binding selectivity |
TBA |
| | 32 |
The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent olanzapine (LY170053) |
TBA |
| | 26 |
BMS-187257, a potent, selective, and novel heterocyclic β3 adrenergic receptor agonist |
TBA |
| | 37 |
The discovery of CP-96,021 and CP-96,486, balanced, combined, potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonists. |
TBA |
| 19492813 |
56 |
Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues. |
Glaxosmithkline |
| 19366244 |
138 |
Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5. |
Astellas Pharma |
| 19362005 |
74 |
Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective beta3-adrenergic receptor agonists. |
Astellas Pharma |
| 19081260 |
10 |
Substituted 1,2,3,4-tetrahydroquinolin-6-yloxypropanes as beta3-adrenergic receptor agonists: design, synthesis, biological evaluation and pharmacophore modeling. |
Central Drug Research Institute |
| 18752946 |
47 |
Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV. |
Astellas Pharma |
| 18701276 |
97 |
Highly functionalized 7-azaindoles as selective PPAR gamma modulators. |
Merck Research Laboratories |
| 18656910 |
2 |
Facile radiosynthesis of fluorine-18 labeled beta-blockers. Synthesis, radiolabeling, and ex vivo biodistribution of [18F]-(2S and 2R)-1-(1-fluoropropan-2-ylamino)-3-(m-tolyloxy)propan-2-ol. |
Centre For Addiction and Mental Health |
| 18640038 |
74 |
Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2. |
Amgen |
| 18553954 |
126 |
Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II. |
Astellas Pharma |
| 17911024 |
37 |
Potent oxindole based human beta3 adrenergic receptor agonists. |
Eli Lilly |
| 17804228 |
44 |
Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists. |
Eli Lilly |
| 17632003 |
55 |
Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity. |
Pfizer |
| 17571866 |
49 |
Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography. |
National Institute of Mental Health |
| 17533126 |
78 |
Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 17524641 |
69 |
3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists. |
Glaxosmithkline |
| 17303428 |
22 |
Novel chiral isoxazole derivatives: synthesis and pharmacological characterization at human beta-adrenergic receptor subtypes. |
Università |
| 16931005 |
21 |
Potent benzimidazolone based human beta(3)-adrenergic receptor agonists. |
Eli Lilly |
| 16722631 |
87 |
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. |
Predix Pharmaceuticals |
| 16392798 |
46 |
Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand. |
Columbia University College of Physicians and Surgeons |
| 16361098 |
70 |
Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists. |
F. Hoffmann-La Roche |
| 15686912 |
35 |
Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety. |
Dainippon Pharmaceutical |
| 15546708 |
35 |
Tryptamine-based human beta3-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives. |
Dainippon Pharmaceutical |
| 15546707 |
60 |
Tryptamine-based human beta3-adrenergic receptor agonists. Part 1: SAR studies of the 7-position of the indole ring. |
Dainippon Pharmaceutical |
| 15177466 |
74 |
BMS-201620: a selective beta 3 agonist. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 15149647 |
10 |
Bridgehead-methyl analog of SC-53116 as a 5-HT4 agonist. |
Pfizer |
| 14643338 |
124 |
Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
Virginia Commonwealth University |
| 12798332 |
35 |
Cyclic amine sulfonamides as linkers in the design and synthesis of novel human beta(3) adrenergic receptor agonists. |
Wyeth Research |
| 12657269 |
52 |
Novel and potent human and rat beta3-adrenergic receptor agonists containing substituted 3-indolylalkylamines. |
Dainippon Pharmaceutical |
| 12361399 |
17 |
Homoazanicotine: a structure-affinity study for nicotinic acetylcholine (nACh) receptor binding. |
Universita Di Camerino |
| 12270184 |
34 |
Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 2: arylethanolaminomethylpiperidines. |
Wyeth Research |
| 12270183 |
45 |
Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 1: aryloxypropanolaminomethylpiperidines. |
Wyeth Research |
| 11720857 |
37 |
4-Aminopiperidine ureas as potent selective agonists of the human beta(3)-adrenergic receptor. |
Wyeth-Ayerst Research |
| 11327605 |
27 |
New oxadiazolidinedione derivatives as potent and selective human beta3 agonists. |
Wyeth-Ayerst Research |
| 11277513 |
25 |
2,4-Thiazolidinediones as potent and selective human beta3 agonists. |
Wyeth-Ayerst Research |
| 11212115 |
72 |
Human beta3 adrenergic receptor agonists containing cyanoguanidine and nitroethylenediamine moieties. |
Merck Research Laboratories |
| 32227883 |
40 |
Isolation and Synthesis of Veranamine, an Antidepressant Lead from the Marine Sponge |
University of Mississippi |
| 31753798 |
49 |
Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent ? |
Shenyang Pharmaceutical University |
| 11055339 |
59 |
Tetrahydroisoquinoline derivatives containing a benzenesulfonamide moiety as potent, selective human beta3 adrenergic receptor agonists. |
Merck Research Laboratories |
| 11052788 |
33 |
Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide. |
Merck Research Laboratories |
| 10999482 |
52 |
Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides. |
Merck Research Laboratories |
| 10987429 |
69 |
Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore. |
Merck Research Laboratories |
| 10915043 |
69 |
Substituted oxazole benzenesulfonamides as potent human beta3 adrenergic receptor agonists. |
Merck Research Laboratories |
| 10888325 |
90 |
Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents. |
Merck Research Laboratories |
| 10888324 |
48 |
Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist. |
Merck Research Laboratories |
| 31625751 |
12 |
Synthesis, Purification, and Selective ? |
Shandong University |
| 32342685 |
325 |
Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D |
National Institute of Neurological Disorders and Stroke |
| 31151791 |
35 |
Development of covalent antagonists for ?1- and ?2-adrenergic receptors. |
Friedrich-Alexander Universit£T Erlangen-N£Rnberg |
| 31042379 |
96 |
Hybridization of ?-Adrenergic Agonists and Antagonists Confers G Protein Bias. |
Friedrich-Alexander University Erlangen-N£Rnberg (Fau) |
| 10406657 |
91 |
Potent, elective human beta3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore. |
Merck Research Laboratories |
| 30875219 |
254 |
Defining Structure-Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D |
University of North Carolina At Chapel Hill |
| 10360736 |
2 |
S1319: a novel beta2-andrenoceptor agonist from a marine sponge Dysidea sp. |
Kirin Brewery |
| 10340609 |
15 |
L-770,644: a potent and selective human beta3 adrenergic receptor agonist with improved oral bioavailability. |
Merck Research Laboratories |
| 10201842 |
69 |
Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides. |
Merck Research Laboratories |
| 10201841 |
47 |
Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides. |
Merck Research Laboratories |
| 31298548 |
112 |
Probing the Existence of a Metastable Binding Site at the ? |
University of Copenhagen |
| 9873681 |
65 |
3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists. |
Merck Research Laboratories |
| 9873496 |
80 |
3-Pyridyloxypropanolamine agonists of the beta 3 adrenergic receptor with improved pharmacokinetic properties. |
Merck Research Laboratories |
| 31185168 |
144 |
Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor. |
Rti International |
| 9871717 |
72 |
Discovery of L-755,507: a subnanomolar human beta 3 adrenergic receptor agonist. |
Merck Research Laboratories |
| 9871716 |
94 |
Potent, selective benzenesulfonamide agonists of the human beta 3 adrenergic receptor. |
Merck Research Laboratories |
| 30392952 |
49 |
Design, synthesis and biological evaluation of 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one derivatives as potent ? |
Shenyang Pharmaceutical University |
| 9379432 |
36 |
Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign pr |
Abbott Laboratories |
| 31613617 |
195 |
Benzyl Phenylsemicarbazides: A Chemistry-Driven Approach Leading to G Protein-Biased Dopamine D |
Friedrich-Alexander-Universit£T Erlangen-N£Rnberg |
| 31620230 |
283 |
3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT |
University of Minnesota Twin Cities |
| 26590100 |
42 |
Discovery of benzamides as potent human ?3 adrenergic receptor agonists. |
Merck And |
| 26565745 |
165 |
Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example. |
Janssen Pharmaceutica |
| 31223445 |
4 |
Computer-Aided Selective Optimization of Side Activities of Talinolol. |
Goethe-University of Frankfurt |
| 8093626 |
13 |
o-Chlorobenzenesulfonamidic derivatives of (aryloxy)propanolamines as beta-blocking/diuretic agents. |
Università |
| 21170122 |
84 |
Comparative 3D QSAR study on ?(1)-, ?(2)-, and ?(3)-adrenoceptor agonists. |
National Institute of Pharmaceutical Education and Research |
| 21075638 |
105 |
Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists. |
Drug Discovery Laboratory |
| 17560786 |
48 |
Synthesis and evaluation of potent and selective beta3 adrenergic receptor agonists containing heterobiaryl carboxylic acids. |
Glaxosmithkline |
| 17129726 |
121 |
3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors. |
Glaxosmithkline |
| 10377236 |
15 |
2-Amino-4-benzyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridines: novel selective beta3-adrenoceptor agonists. |
University of Tennessee |
| 8809159 |
26 |
Iodinated analogs of trimetoquinol as highly potent and selective beta 2-adrenoceptor ligands. |
University of Tennessee-Memphis |
| 29751236 |
46 |
Synthesis and biological evaluation of ? |
Shenyang Pharmaceutical University |
| 29574204 |
54 |
Design and synthesis of aryloxypropanolamine as ? |
East China Normal University |
| 29656199 |
148 |
Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties. |
University of Texas At Austin |
| 29851481 |
122 |
Discovery of ?-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy. |
University of Florence |
| 29631962 |
252 |
Identification and biological evaluation of thiazole-based inverse agonists of ROR?t. |
Phenex Pharmaceuticals |
| 28355078 |
34 |
Discovery of Novel Indazole Derivatives as Orally Available? |
Asahi Kasei Pharma |
| 29589445 |
154 |
1-[3-(4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1) as a Model for the Rational Design of a Novel Class of Brain Penetrant Ligands with High Affinity and Selectivity for Dopamine D |
Universit£ |
| 1347318 |
52 |
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents. |
Berlex Laboratories |
| 26833890 |
18 |
Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease. |
Yogi Vemana University |
| 27128689 |
28 |
Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2. |
National Institutes of Health |
| 26469307 |
7 |
Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b. |
University of Leipzig |
| 2172674 |
5 |
Amplification of the rat M2 muscarinic receptor gene by the polymerase chain reaction: functional expression of the M2 muscarinic receptor. |
University of Arizona |
Search and Browse
